In this study, we compared the efficacy of regular regimens patients received at our center and investigated the potential antitumor effect of anlotinib or in combination with osimertinib in EGFR‐T790M mutant osimertinib‐resistant NSCLC cell line. This evidence concerns the gene EGFR and non-small cell lung carcinoma.